Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study. Background: Schirous type cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results